Stereoselective Synthesis of E1 Enzyme Inhibitor Intermediates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The efficient chemical synthesis of 4-substituted ((1S,2S,4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are effective E1 activating enzyme inhibitors, is challenging due to the complexity of stereogenic centers in these compounds.
Innovation Solution
The synthesis of 4-substituted ((1S,2S,4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates involves specific processes and intermediates, including combining compounds of formulas (II) and (III) to form compounds of formula (I), followed by steps such as treating with an amine to form compound (V) and subsequent sulfamoylation, to produce effective E1 activating enzyme inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional synthesis methods are used to produce 4-substituted ((1S,2S,4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, then the compounds can be synthesized, but the synthesis efficiency is low due to the complexity of multiple stereogenic centers
Solution Approach 1:
The patent divides the synthesis into distinct stages: first forming the core cyclopentyl-pyrrolopyrimidin structure with controlled stereochemistry, then separately introducing the sulfamate group. This segmentation allows each step to be optimized independently, improving overall synthesis efficiency despite the complex molecular structure with multiple stereogenic centers
Solution Approach 2:
The patent employs preliminary stereochemical control during the formation of the cyclopentyl ring system, establishing the correct (1S,2S,4R) configuration early in the synthesis. This preliminary action prevents the need for complex stereoselective modifications later, thereby improving synthesis efficiency for compounds with multiple stereogenic centers
2Reliability
If multiple stereogenic centers are present in the compound structure, then the biological activity and specificity are improved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent applies local quality control by using stereoselective reagents and conditions specifically at the stages where stereogenic centers are formed. The synthesis methodology incorporates chiral catalysts or chiral auxiliaries at critical steps to ensure high stereochemical purity, thereby maintaining biological activity while managing manufacturing precision requirements
Solution Approach 2:
The patent utilizes parameter changes in the form of temperature control, solvent selection, and catalyst optimization during stereoselective steps. By carefully adjusting these parameters, the synthesis achieves high stereochemical purity for the (1S,2S,4R) configuration, ensuring both biological activity and manufacturability
Data Source
AI summary
The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((1S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.